Healthcare: Who Had the Better Quarter, Gilead Sciences or Amgen?
It's a battle of the big bio's on this episode of Industry Focus Healthcare. Is Gilead Sciences finally overcoming its hep C headwind? Is Amgen beating back biosimilars? We dig into the details as we discuss which of these biopharma behemoths delivered better first quarter results. Stocks: GILD, AMGN Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter